IBKS No2 SPAC (KQ:204840) — Market Cap & Net Worth
Market Cap & Net Worth: IBKS No2 SPAC (204840)
IBKS No2 SPAC (KQ:204840) has a market capitalization of $44.15 Million (₩65.14 Billion) as of October 12, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22425 globally and #1456 in its home market, demonstrating a -0.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IBKS No2 SPAC's stock price ₩4200.00 by its total outstanding shares 15509797 (15.51 Million).
IBKS No2 SPAC Market Cap History: 2015 to 2026
IBKS No2 SPAC's market capitalization history from 2015 to 2026. Data shows growth from $19.78 Million to $44.15 Million (7.61% CAGR). Check current stock price of IBKS No2 SPAC for real-time trading data and today's change.
Index Memberships
IBKS No2 SPAC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$256.95 Billion | 0.02% | #710 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$256.95 Billion | 0.02% | #710 of 1384 |
Weight: IBKS No2 SPAC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
IBKS No2 SPAC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IBKS No2 SPAC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 204840 cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.00x
IBKS No2 SPAC's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.92x
IBKS No2 SPAC's market cap is 0.92 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $41.04 Million | $4.64 Billion | -$5.49 Billion | 0.01x | N/A |
| 2017 | $35.80 Million | $2.41 Billion | -$4.24 Billion | 0.01x | N/A |
| 2018 | $35.85 Million | $8.00 Billion | -$5.35 Billion | 0.00x | N/A |
| 2019 | $11.56 Million | $10.61 Billion | -$5.52 Billion | 0.00x | N/A |
| 2020 | $15.24 Million | $11.99 Billion | -$3.36 Billion | 0.00x | N/A |
| 2021 | $13.03 Million | $12.43 Billion | -$3.73 Billion | 0.00x | N/A |
| 2022 | $7.88 Million | $16.73 Billion | -$790.17 Million | 0.00x | N/A |
| 2023 | $11.94 Million | $26.03 Billion | -$3.75 Billion | 0.00x | N/A |
| 2024 | $10.27 Million | $26.05 Billion | -$2.34 Billion | 0.00x | N/A |
| 2025 | $11.47 Million | $35.27 Billion | $12.49 Million | 0.00x | 0.92x |
Competitor Companies of 204840 by Market Capitalization
Companies near IBKS No2 SPAC in the global market cap rankings as of October 12, 2026. See 204840 net asset quality score to understand what proportion of total assets are financed by equity.
Key companies related to IBKS No2 SPAC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #526 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #526 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
IBKS No2 SPAC Historical Marketcap From 2015 to 2026
Between 2015 and today, IBKS No2 SPAC's market cap moved from $19.78 Million to $ 44.15 Million, with a yearly change of 7.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩44.15 Million | +284.97% |
| 2025 | ₩11.47 Million | +11.67% |
| 2024 | ₩10.27 Million | -14.00% |
| 2023 | ₩11.94 Million | +51.47% |
| 2022 | ₩7.88 Million | -39.52% |
| 2021 | ₩13.03 Million | -14.48% |
| 2020 | ₩15.24 Million | +31.82% |
| 2019 | ₩11.56 Million | -67.75% |
| 2018 | ₩35.85 Million | +0.14% |
| 2017 | ₩35.80 Million | -12.77% |
| 2016 | ₩41.04 Million | +107.50% |
| 2015 | ₩19.78 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 11th, 2026 the market cap of IBKS No2 SPAC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.15 Million USD |
| MoneyControl | $44.15 Million USD |
| MarketWatch | $44.15 Million USD |
| marketcap.company | $44.15 Million USD |
| Reuters | $44.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more